查看文章

Background:

Both dolutegravir and efavirenz are known to be effective in pregnancy and postpartum to prevent vertical transmission of HIV and to maintain maternal health. Both drugs have also been associated with neuropsychiatric symptoms. To what extent, these symptoms occur in pregnant and postpartum women, however, is not yet known.

Methods:

This was a secondary analysis of the DolPHIN2 study, a multicentre randomized trial among women presenting late in pregnancy with untreated HIV–who received either a dolutegravir-containing or efavirenz-containing regimen. Longitudinal measures of depression, anxiety and sleep quality were analysed during pregnancy and up to 48 weeks postpartum.

Results:

Among 268 women, median (IQR) Edinburgh Post Natal Depression Score (EPDS) scores were 8 (3–11) and highest at enrolment. In the dolutegravir and efavirenz arm, respectively, 23.7 and 25.6 …